Cytochrome p450-dependent metabolism of ω-6 and ω-3 long-chain polyunsaturated fatty acids

Pharmacological Reports

Volumn 62, Issue 3, 2010, Pages 536-547

  Arnold, Cosima ^a   Konkel, Anne ^a   Fischer, Robert ^a   Schunck, Wolf Hagen ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Arachidonic acid; Cardiovascular disease; Cytochrome p450; Docosahexaenoic acid; Eicosanoids; Eicosapentaenoic acid; 3 fatty acids

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ANGIOTENSIN II; ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 4A; DOCOSAHEXAENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPOXYGENASE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OXIDOREDUCTASE; PROTEIN CYP4F; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; ARACHIDONATE EPOXYGENASE; CARDIOTONIC AGENT; HYDROXYICOSATETRAENOIC ACID;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FAT INTAKE; FATTY ACID METABOLISM; HEART ARRHYTHMIA; HEART DEATH; HEART FUNCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; METABOLIC REGULATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; METABOLISM;

ANIMALS; ARACHIDONIC ACID; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DEATH, SUDDEN, CARDIAC; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; EPOXIDE HYDROLASES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS;

EID: 77954856325     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70311-X     Document Type: Review

References (107)

1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenzanell Infarto miocardico. Lancet, 1999, 354, 447-455.
2. Abdukeyum GG, Owen AJ, McLennan PL: Dietary (n-3) long-chain polyunsaturated fatty acids inhibit ischemia and reperfusion arrhythmias and infarction in rat heart not enhanced by ischemic preconditioning. J Nutr, 2008, 138, 1902-1909.
3. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD et al.: Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA, 2007, 104, 9018-9023.
4. Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y et al.: Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA, 2009, 106, 564-569.
5. Bang HO, Dyerberg J, Hjoorne N: The composition of food consumed by Greenland Eskimos. Acta Med Scand, 1976, 200, 69-73.
6. Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunck WH: Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun, 2005, 329, 1275-1281.
7. Blanton A, Nsaif R, Hercule H, Oyekan A: Nitric oxide/cytochrome P450 interactions in cyclosporin A-induced effects in the rat. J Hypertens, 2006, 24, 1865-1872.
8. Calder PC: Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids, 2006, 75, 197-202.
9. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A et al.: N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol, 2005, 45, 1723-1728.
10. Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res, 1996, 78, 415-423.
11. Capdevila JH, Falck JR: Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat, 2002, 68-69, 325-344.
12. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, Jr., Schwartzman ML: 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol, 2008, 294, H1018-1026.
13. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, Falck JR, Patel PK et al: Multiple anti-apoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardio myocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol, 2008, 294, H724-735.
14. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet, 1978, 2, 117-119.
15. Fer M, Corcos L, Dreano Y, Plee-Gautier E, Salaun JP, Berthou F, Amet Y: Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J Lipid Res, 2008, 49, 2379-2389.
16. Fer M, Dreano Y, Lucas D, Corcos L, Salaun JP, Berthou F, Amet Y: Metabolism of eicosapentaenoic and docosa-hexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys, 2008, 471, 116-125.
17. Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F, Park JK et al.: Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension, 2008, 51, 540-546.
18. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I. Busse R: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999, 401, 493-497.
19. Fleming I: Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat, 2007, 82, 60-67.
20. Fleming I: Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med, 2008, 18, 20-25.
21. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 2001, 294, 1871-1875.
22. Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, Gross GJ: Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol, 2004, 37, 1245-1249.
23. Gross GJ, Hsu A, Falck JR, Nithipatikom K: Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol, 2007, 42,687-691.
24. Gryglewski RJ: Prostacyclin among prostanoids. Pharmacol Rep, 2008, 60, 3-11.
25. Gryglewski RJ, Salmon JA, Ubatuba FB, Weatherly BC, Moncada S, Vane JR: Effects of all cis-5,8,11,14,17-eicosapentaenoic acid and PGH3 on platelet aggregation. Prostaglandins, 1979, 18,453-478.
26. Harmon SD, Fang X, Kaduce TL, Hu S, Raj Gopal V, Falck JR, Spector AA: Oxygenation of ω-3 fatty acids by human cytochrome P450 4F3B: effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins Leukot Essent Fatty Acids, 2006, 75, 169-177.
27. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis, 2008, 197, 12-24.
28. Hata AN, Breyer RM: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther, 2004, 103, 147-166.
29. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, Greenland P: Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation, 2004,109,2705-2711.
30. Hercule HC, Salanova B, Essin K, Honeck H, Falck JR, Sausbier M, Ruth P et al.: The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK a channel subunit in rodents. Exp Physiol, 2007, 92, 1067-1076.
31. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves A et al.: Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol, 2009, 29, 54-60.
32. Hoagland KM, Flasch AK, Roman RJ: Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension, 2003, 42, 669-673.
33. Honeck H, Gross V, Erdmann B, Kargel E, Neunaber R, Milia AF, Schneider W et al.: Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticoster-one acetate-salt hypertensive mice. Hypertension, 2000, 36,610-616.
34. Hutchens MP, Nakano T, Dunlap J, Traystman RJ, Hurn PD, Alkayed NJ: Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation, 2008, 76, 89-94.
35. Imig JD: Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol, 2005, 289, F496-503.
36. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension, 2002, 39, 690-694.
37. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD: Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat, 2007, 82, 42-49.
38. Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, Laniado-Schwartzman M: 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-KB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther, 2008, 324, 103-110.
39. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J et al.: Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res, 2007, 67, 6665-6674.
40. Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem, 2002, 277, 8755-8758.
41. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I: Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension, 2005, 45, 759-765.
42. Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M: Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Biochem Biophys Res Commun, 2004, 315, 679-685.
43. Keseru B, Barbosa-Sicard E, Popp R, Fisslthaler B, Dietrich A, Gudermann T, Hammock BD et al.: Epoxyeiωsatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J, 2008, 22, 4306-4315.
44. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 2002, 106, 2747-2757.
45. Kromhout D, Bosschieter EB, de Lezenne Coulander C: The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med, 1985,312,1205-1209.
46. Lands WE: Dietary fat and health: the evidence and the politics of prevention: careful use of dietary fats can improve life and prevent disease. Ann NY Acad Sci, 2005, 1055, 179-192.
47. Lauterbach B, Barbosa-Sicard E, Wang MH, Honeck H, Kargel E, Theuer J, Schwartzman ML et al.: Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension, 2002, 39, 609-613.
48. Lavie CJ, Milani RV, Mehra MR, Ventura HO: Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol, 2009, 54, 585-594.
49. Leaf A, Kang JX, Xiao YF, Billman GE: Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation, 2003, 107, 2646-2652.
50. Lee HC, Lu T, Weintraub NL, VanRollins M, Spector AA, Shibata EF: Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol, 1999, 519 Pt 1, 153-168.
51. Liclican EL, McGiff JC, Falck JR, Carroll MA: Failure to upregulate the adenosine2Areceptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats. Am J Physiol Renal Physiol, 2008, 295, F1696-1704.
52. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L: Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys, 2007, 47, 87-98.
53. Loot AE, Popp R, Fisslthaler B, Vriens J, Nilius B, Fleming I: Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res, 2008, 80, 445-452.
54. + channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol, 2001,537,811-827.
55. + channels by epoxyeicosatrienoic acids: a structural determinant study. Mol Pharmacol, 2002, 62, 1076-1083.
56. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG et al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Soprav vivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation, 2002, 105, 1897-1903.
57. Matthan NR, Jordan H, Chung M, Lichtenstein AH, Lathrop DA, Lau J: A systematic review and meta-analysis of the impact of ω-3 fatty acids on selected arrhythmia outcomes in animal models. Metab Clin Exp, 2005,54,1557-1565.
58. McGiff JC, Quilley J: 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol, 1999, 277, R607-623.
59. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, Heuser A et al.: Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet, 2008, 40, 529-537.
60. Morin C, Sirois M, Echave V, Rizcallah E, Rousseau E: Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol, 2009, 296, L130-139.
61. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM: Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol, 2008,295, H2128-2134.
62. Mozaffarian D: Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J ClinNutr, 2008, 87, 1991S-1996S.
63. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M et al.: Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J, 2007, 403, 109-118.
64. Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, Markovic M et al.: A peroxisome proliferator-activated receptor α-activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol, 2004, 164, 521-532.
65. Nguyen X, Wang MH, Reddy KM, Falck JR, Schwartzman ML: Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol, 1999, 276, R1691-1700.
66. Nithipatikom K, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ: Effects of selective inhibition of cytochrome P-450 ω-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol, 2006, 290, H500-505.
67. Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ: Inhibition of cytochrome P450ω-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res, 2004, 95, e65-71.
68. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 1999, 285, 1276-1279.
69. Peters-Golden M, Henderson WR Jr.: Leukotrienes. N Engl J Med, 2007, 357, 1841-1854.
70. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, Fleming I et al.: Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens, 2009, 27, 322-331.
71. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev, 2002, 82, 131-185.
72. Roman RJ, Alonso-Galicia M, Wilson TW: Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Am J Hypertens, 1997,10, 63S-67S.
73. Russo GL: Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol, 2009, 77, 937-946.
74. Schwarz D, Kisselev P, Chernogolov A, Schunck WH, Roots I: Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem Biophys Res Commun, 2005, 336, 779-783.
75. Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, Schunck WH, Roots I: Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol, 2004, 67, 1445-1457.
76. Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol, 2008, 8, 349-361.
77. + channels and p42/p44 MAPK pathway. Circ Res, 2004, 95, 506-514.
78. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K et al.: Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res, 2006, 99, 442-450.
79. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ: Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat, 2007, 82, 50-59.
80. Simopoulos AP: The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood), 2008, 233, 674-688.
81. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD: Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol, 2009, 174, 2086-2095.
82. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML: Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgeninduced hypertension. Hypertension, 2007, 50, 123-129.
83. Singh H, Schwartzman ML: Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep, 2008, 60, 29-37.
84. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD: Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA, 2005,102,2186-2191.
85. Spector AA: Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res, 2009, 50 Suppl, S52-56.
86. Spiecker M, Liao JK: Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys, 2005, 433, 413-420.
87. Stark K, Wongsud B, Burman R, Oliw EH: Oxygenation of polyunsaturated long chain fatty acids by recombinant CYP4F8 and CYP4F12 and catalytic importance of Tyr-125 and Gly-328 of CYP4F8. Arch Biochem Biophys, 2005, 441, 174-181.
88. Sun P, Lin DH, Wang T, Babilonia E, Wang Z, Jin Y, Kemp R et al.: Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC. Am J Physiol Renal Physiol, 2006, 291, F1192-1200.
89. Terano T, Salmon JA, Moncada S: Biosynthesis and biological activity of leukotriene B5. Prostaglandins, 1984, 27, 217-232.
90. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ et al.: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet, 2003, 361, 477-485.
91. Van Rollins M, Frade PD, Carretero OA: Oxidation of 5,8,11,14,17-eicosapentaenoic acid by hepatic and renal microsomes. Biochim Biophys Acta, 1988, 966, 133-149.
92. VanRollins M, Baker RC, Sprecher HW, Murphy RC: Oxidation of docosahexaenoic acid by rat liver microsomes. J Biol Chem, 1984, 259, 5776-5783.
93. von Schacky C: Use of red blood cell fatty-acid profiles as biomarkers in cardiac disease. Biomark Med, 2009, 3, 25-32.
94. von Schacky C, Harris WS: Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res, 2007, 73, 310-315.
95. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C et al.: Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem, 2007, 282, 22254-22266.
96. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB et al.: Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther, 2003, 307, 753-764.
97. Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS et al.: Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res, 2006, 98, 962-969.
98. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC: Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem, 1996, 271, 3460-3468.
99. + channel activities by epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat, 2007, 82, 11-18.
100. 2+ channels and contraction in mammalian heart cells. J Physiol, 1998, 508, 777-792.
101. 2+ currents in transgenic mice with cardiacspecific overexpression of CYP2J2. Mol Pharmacol, 2004,66,1607-1616.
102. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH et al.: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA, 2006, 103, 18733-18738.
103. Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H et al.: Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol, 2007, 293, H142-151.
104. 125I-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther, 2008, 324, 1019-1027.
105. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, Van-Rollins M: Cytochrome P-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther, 2002, 303,768-776.
106. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C et al.: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res, 2000, 87, 992-998.
107. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M: EET homologs potently dilate coronary microvessels and activate BKca channels. Am J Physiol Heart Circ Physiol, 2001, 280, H2430-2440.